Regency Fincorp is a non-banking financial company that provides secured loans to small and medium-sized businesses and short-term digital salary advances to individual employees, primarily in Northern India.
The company operates in a highly fragmented and competitive lending market where capital is a commodity. While they claim a technology edge through their 'Cash My Salary' app, the low average ROCE of 4.8% and ROE of 2.6% indicate a lack of durable competitive advantage or pricing power.
Management has focused on aggressive AUM growth through frequent equity dilution and NCD issuances. While they are pivoting from risky unsecured group lending to secured MSME loans, the historical returns on equity have been poor, suggesting capital is being deployed at rates barely above the cost of funds.
The company's aggressive pursuit of AUM growth through high-cost debt and frequent equity dilution eventually hit a wall as credit quality deteriorated. The jump in Net NPAs was a harbinger of systemic weakness in the MSME portfolio, and the 13-14% cost of capital left no room for error. As the revolving door of key financial officers continued, internal controls failed to catch a spike in defaults, leading to a liquidity crunch where the cost of borrowing exceeded the yield on assets, effectively vaporizing shareholder equity.
RichFakir rates Regency Fincorp Ltd's business quality as poor — 34/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Regency Fincorp Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Regency Fincorp Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Regency Fincorp Ltd's fair value is about ₹5 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →